C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: 245B KRW
Have any thoughts about
Cellivery Therapeutics Inc?
Write Note

Intrinsic Value

Cellivery Therapeutics Inc's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 499.84 KRW. Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 78%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
1 499.84 KRW
Overvaluation 78%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Cellivery Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Cellivery Therapeutics Inc cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Cellivery Therapeutics Inc?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Cellivery Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Cellivery Therapeutics Inc

Provide an overview of the primary business activities
of Cellivery Therapeutics Inc.

What unique competitive advantages
does Cellivery Therapeutics Inc hold over its rivals?

What risks and challenges
does Cellivery Therapeutics Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cellivery Therapeutics Inc.

Provide P/S
for Cellivery Therapeutics Inc.

Provide P/E
for Cellivery Therapeutics Inc.

Provide P/OCF
for Cellivery Therapeutics Inc.

Provide P/FCFE
for Cellivery Therapeutics Inc.

Provide P/B
for Cellivery Therapeutics Inc.

Provide EV/S
for Cellivery Therapeutics Inc.

Provide EV/GP
for Cellivery Therapeutics Inc.

Provide EV/EBITDA
for Cellivery Therapeutics Inc.

Provide EV/EBIT
for Cellivery Therapeutics Inc.

Provide EV/OCF
for Cellivery Therapeutics Inc.

Provide EV/FCFF
for Cellivery Therapeutics Inc.

Provide EV/IC
for Cellivery Therapeutics Inc.

Compare the intrinsic valuations
of Cellivery Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cellivery Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cellivery Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cellivery Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cellivery Therapeutics Inc with its peers.

Analyze the financial leverage
of Cellivery Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cellivery Therapeutics Inc.

Provide ROE
for Cellivery Therapeutics Inc.

Provide ROA
for Cellivery Therapeutics Inc.

Provide ROIC
for Cellivery Therapeutics Inc.

Provide ROCE
for Cellivery Therapeutics Inc.

Provide Gross Margin
for Cellivery Therapeutics Inc.

Provide Operating Margin
for Cellivery Therapeutics Inc.

Provide Net Margin
for Cellivery Therapeutics Inc.

Provide FCF Margin
for Cellivery Therapeutics Inc.

Show all solvency ratios
for Cellivery Therapeutics Inc.

Provide D/E Ratio
for Cellivery Therapeutics Inc.

Provide D/A Ratio
for Cellivery Therapeutics Inc.

Provide Interest Coverage Ratio
for Cellivery Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cellivery Therapeutics Inc.

Provide Quick Ratio
for Cellivery Therapeutics Inc.

Provide Current Ratio
for Cellivery Therapeutics Inc.

Provide Cash Ratio
for Cellivery Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cellivery Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cellivery Therapeutics Inc?

What is the current Free Cash Flow
of Cellivery Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cellivery Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cellivery Therapeutics Inc

Current Assets 5.7B
Cash & Short-Term Investments 589.8m
Receivables 1.8B
Other Current Assets 3.3B
Non-Current Assets 20.2B
Long-Term Investments 1.1B
PP&E 17.8B
Intangibles 438.8m
Other Non-Current Assets 957.6m
Current Liabilities 53.9B
Accounts Payable 2.9B
Accrued Liabilities 6.5B
Short-Term Debt 16.1B
Other Current Liabilities 28.4B
Non-Current Liabilities -725.6m
Long-Term Debt 368.7m
Other Non-Current Liabilities -1.1B
Efficiency

Earnings Waterfall
Cellivery Therapeutics Inc

Revenue
22.7B KRW
Cost of Revenue
-22.4B KRW
Gross Profit
248.7m KRW
Operating Expenses
-18.6B KRW
Operating Income
-18.3B KRW
Other Expenses
9.6B KRW
Net Income
-8.7B KRW

Free Cash Flow Analysis
Cellivery Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROE
Exceptional 1-Year Revenue Growth
ROE is Increasing
32/100
Profitability
Score

Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Short-Term Solvency
18/100
Solvency
Score

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Cellivery Therapeutics Inc

There are no price targets for Cellivery Therapeutics Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Cellivery Therapeutics Inc?

Click here to dive deeper.

Dividends

Cellivery Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for Cellivery Therapeutics Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Cellivery Therapeutics Inc

Country

Korea

Industry

Life Sciences Tools & Services

Market Cap

244.9B KRW

Dividend Yield

0%

Description

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Contact

SEOUL
Seoul
9F, K-BIZ DMC Tower, 189, Seongam-ro, Mapo-gu
+82231518900
www.cellivery.com

IPO

2018-11-09

Employees

87

Officers

See Also

Discover More
What is the Intrinsic Value of one Cellivery Therapeutics Inc stock?

The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 499.84 KRW.

Is Cellivery Therapeutics Inc stock undervalued or overvalued?

Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 78%.

Back to Top